Please login to the form below

Not currently logged in
Email:
Password:

Vaccibody name Martin Bonde as CEO

He joins from EpiTherapeutics where he holds the same role

martin bonde vaccibodyNorwegian cancer vaccine company Vaccibody has appointed Dr Martin Bonde as CEO, effective from August 10.

Bonde has over 25 years of international experience in the biotech industry, starting his career at Dako and going on to work at companies including Ostemeter, Visiopharm and Aros Pharma. 

He joins from EpiTherapeutics, where he has held the role of CEO since 2009.

Tom Pike, chairman of Vaccibody, said: "We are delighted to welcome Martin Bonde to Vaccibody. The Vaccibody technology has a wide business development potential within many market segments, which will benefit greatly from Martin's extensive track record in deal making. 

“We also believe that our ability to attract an experienced industry executive with Martin's credentials reflect positively on Vaccibody's' considerable potential”.

Bonde's experience in the sector includes a number of transactions within business development, trade sales, mergers and acquisitions and management of research and development.

1st July 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics